Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Esperion Therapeutics, Inc.
< Previous
1
2
Next >
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
November 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
November 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
June 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
June 15, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
June 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
June 05, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
June 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
May 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Jefferies Healthcare Conference
May 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 12, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports First Quarter 2023 Financial Results
May 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 04, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in JMP Securities Life Sciences Conference
May 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
April 27, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
April 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
April 19, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
April 03, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.